TAT 2017
 
Monday, March 6, 2017
09:00 - 10:15Plenary Session 1: Opening Ceremony [More Info]
Chair: Jean-Charles Soria, Institut Gustave Roussy, Villejuif, France
Chair: Giuseppe Giaccone, Georgetown University, Washington, DC, USA
09:00 - 09:07Opening Address on behalf of Gustave Roussy [More Info]
Alexander Eggermont, Institut Gustave Roussy, Villejuif, France
09:07 - 09:15Opening Address on behalf of TAT 2017 Organizing Committee [More Info]
Jean-Charles Soria, Institut Gustave Roussy, Villejuif, France
09:15 - 09:45O1.1 TAT 2017 Honorary Award Invited Lecture: Immunologic Checkpoint Blockade: Exploring Combinations and Mechanisms [More Info]
Jedd Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY, USA
09:45 - 10:15O1.2 Keynote Lecture: Positioning Immune checkpoint blockade within the systemic anti-cancer armamentarium [More Info]
Alexander Eggermont, Institut Gustave Roussy, Villejuif, France


10:15 - 10:40Break [More Info]


10:40 - 12:20Plenary Session 2: Immuno-oncology (1): Novel combinations, novel approaches [More Info]
Chair: Alexander Eggermont, Institut Gustave Roussy, Villejuif, France
Chair: Aurélien Marabelle, Institut Gustave Roussy, Villejuif, France
10:40 - 11:00O2.1 Customizing cancer immunotherapies to match the intrinsic tumor microenvironment [More Info]
Brad Nelson, British Columbia Cancer Agency, Vancouver, Canada
11:00 - 11:20O2.2 Combining IO with IO: rationale and clinical perspectives [More Info]
Ignacio Melero, University of Navarra, Navarra, Spain
11:20 - 11:40O2.3 Clinical stage: Immune Design (TLR-4 agonist) [More Info]
Carlos Paya, Immune Design, South San Francisco, CA, USA
11:40 - 12:00O2.4 Turning Tumor Mutations into Personalized Cancer Therapies [More Info]
Roman Yelensky, Gritstone Oncology, Cambridge, MA, USA
12:00 - 12:20General discussion


12:20 - 13:35Lunch & Poster Viewing


13:35 - 13:45Welcome address on behalf of ESMO [More Info]
Josep Tabernero, VHIO/Vall d’Hebron University Hospital, Barcelona, Spain
13:45 - 15:15Plenary Session 3: Phase 1 Studies - Completed or in progress (miscellaneous drugs & targets) [More Info]
Chair: Lesley Seymour, Canadian Cancer Trials Group, Kingston, Canada
Chair: Udai Banerji, The Institute of Cancer Research and The Royal Marsden, London, UK
13:45 - 14:00O3.1 A Phase 1/1b, first-in-human study of IPI-549, a PI3K-? inhibitor and myeloid targeting agent, as monotherapy and in combination with nivolumab in patients with advanced solid tumors [More Info]
Anthony Tolcher, South Texas Accelerated Research Therapeutics, San Antonio, TX, USA
14:00 - 14:15O3.2 TAX-TORC: investigator initiated phase I trial of vistusertib (AZD2014), a dual m-TORC1/2 inhibitor, in combination with weekly paclitaxel [More Info]
Udai Banerji, The Institute of Cancer Research and The Royal Marsden, London, UK
14:15 - 14:30O3.3. Phase I/II Study of AC0010 in Patients with EGFR T790M Mutant Non-Small Cell Lung Cancer (NSCLC) [More Info]
Yi-Long Wu, Guangdong Lung Cancer Institute, Guangdong General hospital, Guangzhou, China
14:30 - 14:45O3.4 Phase IB study of CC-122 and obinutuzumab in relapsed or refractory diffuse large B-cell lymphoma and indolent non-Hodgkin lymphoma [More Info]
Jean-Marie Michot, Institut Gustave Roussy, Villejuif, France
14:45 - 15:00O3.5 Preliminary evidence of clinical activity with tipifarnib in squamous cell carcinomas of the head & neck (SCCHN) with HRAS mutations. [More Info]
Alan Ho, Memorial Sloan Kettering Cancer Center, New York, NY, USA
15:00 - 15:15O3.6 Model-based dose escalation of phase I trials in Japanese patients. Could it be more efficient than rule-based designs? [More Info]
Akihiko Shimomura, National Cancer Center Hospital, Tokyo, Japan


15:15 - 15:45Break [More Info]


15:45 - 17:25Plenary Session 4: Early-phase drug development in hematology [More Info]
Chair: Vincent Ribrag, Institut Gustave Roussy, Villejuif, France
15:45 - 16:05O4.1 Targeting epigenetics in hematological malignancies [More Info]
Scott Ribich, Epizyme, Cambridge, MA, USA
16:05 - 16:25O4.2 CAR T-cells, do we need new modified CAR T-cell designs? [More Info]
Loan Hoang-Sayag, Cellectis, Paris, France
16:25 - 16:45O4.3 Targeting RNA splicing in cancer [More Info]
Peter Smith, H3 Biomedicine, Arlington, MA, USA
16:45 - 17:05O4.4 BiTEs: what are the next steps? [More Info]
Ralf Bargou, Comprehensive Cancer Center Mainfranken, Universitätsklinikum Würzburg, Würzburg, Germany
17:05 - 17:25General discussion


17:25 - 17:45Poster Awarding Ceremony [More Info]
Chair: Jean-Charles Soria, Institut Gustave Roussy, Villejuif, France
Chair: Giuseppe Giaccone, Georgetown University, Washington, DC, USA
17:25 - 17:30Introduction Poster Awards
17:30 - 17:37P4.2 Potentiation of targeted breast cancer therapy through CDK8/19 inhibition [More Info]
Eugenia Broude, University of South Carolina, Columbia, SC, United States
17:37 - 17:45P7.4 Loss of Axin1 drives acquired resistance to WNT pathway blockade in colorectal cancers cells carrying RSPO3 fusions [More Info]
Erica Torchiaro, Candiolo Cancer Institute – FPO IRCCS, Turin, Italy


17:45 - 19:00Poster Viewing & Reception [More Info]
 
Tuesday, March 7, 2017
08:30 - 10:10Plenary Session 5: Immuno-oncology (2): Novel immune modulators [More Info]
Chair: Aurélien Marabelle, Institut Gustave Roussy, Villejuif, France
Chair: Philippe Bedard, Princess Margaret Cancer Centre, Toronto, Canada
08:30 - 08:50O5.1 New Combinations in Immunotherapy: TLR9 Agonist + Anti-PD-1 Therapy [More Info]
Robert Janssen, Dynavax Technologies, Berkeley, CA, USA
08:50 - 09:10O5.2 Bugs as Drugs, on the way to becoming a reality [More Info]
Laura Rosa Brunet, Immodulon Therapeutics, Uxbridge, United Kingdom
09:10 - 09:30O5.3 Combining immune checkpoints with cytotoxic chemotherapies [More Info]
François Ghiringhelli, Centre Georges-François Leclerc, Dijon Cedex, France
09:30 - 09:50O5.4 Boosting Immunity and The Cancer Immune Setpoint [More Info]
Daniel Chen, Genentech, San Francisco, CA, USA
09:50 - 10:10General discussion


10:15 - 10:40Break


10:40 - 12:20Plenary Session 6: Targeting the cell cycle [More Info]
Chair: David Hyman, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Chair: Gary Schwartz, Columbia University, New York, NY, USA
10:40 - 11:00O6.1 The Targeting of CDK4/6 Signaling Pathway: Defining a Biomarker for Response [More Info]
Gary Schwartz, Columbia University, New York, NY, USA
11:00 - 11:20O6.2 Exploring transcription-mediated replication stress and RNA-DNA hybrids as targets of anticancer drugs [More Info]
Andrés Aguilera, University of Seville, Sevilla, Spain
11:20 - 11:40O6.3 Exploiting the potential of ATR inhibitors [More Info]
Timothy Yap, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
11:40 - 12:00O6.4 MTH1 inhibitors and oxidative stress [More Info]
Thomas Helleday, SciLifeLab, Stockholm, Sweden
12:00 - 12:20General discussion


12:20 - 13:30Lunch
12:30 - 13:30Meet-the-Professor Session: How to give a talk and how to write a paper: Tips to advance your career [More Info]
Lee Ellis, MD Anderson Cancer Center, Houston, TX, USA


13:30 - 15:30Plenary Session 7: Targeted drug delivery: Next-generation antibody-drug conjugates and nanomedicines [More Info]
Chair: Giuseppe Giaccone, Georgetown University, Washington, DC, USA
Chair: Anthony Tolcher, South Texas Accelerated Research Therapeutics, San Antonio, TX, USA
13:30 - 13:50O7.1 Abbvie/CytomX program on ADCs [More Info]
Rachel Humphrey, CytomX Therapeutics, South San Francisco, CA, USA
13:50 - 14:10O7.2 DCs with diverse payloads of tumor-killing agents [More Info]
Donald A. Bergstrom, Mersana Therapeutics, Cambridge, MA, USA
14:10 - 14:30O7.3 Rovalpituzumab tesirine (Rova-T) [More Info]
Giuseppe Giaccone, Georgetown University, Washington, DC, USA
14:30 - 14:50O7.4 New generation antibody-directed nanotherapeutics [More Info]
Andrew Sawyer, Merrimack Pharmaceuticals, Boston, MA, USA
14:50 - 15:10O7.5 Paving a Novel Approach to Developing Anticancer Combinations through Tumor-Targeting Nanomedicines [More Info]
Lawrence D. Mayer, Jazz Pharmaceuticals, Vancouver, Canada
15:10 - 15:30General discussion


15:30 - 16:00Break


16:00 - 17:50Plenary Session 8: Clinical genomic profiling in early-phase clinical studies [More Info]
Chair: Martijn Lolkema, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
Chair: Filip Janku, The University Texas MD Anderson Cancer Center, Houston, TX, USA
16:00 - 16:20O8.1 Educational introduction: Genomic profiling techniques. Their pros and cons. [More Info]
Maria Arcila, Memorial Sloan Kettering Cancer Center, New York, NY, USA
16:20 - 16:50Controversy: “We Need Genomics in Early-Phase Drug Development”
16:20 - 16:40Pro presentation [More Info]
Emile Voest, Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands
16:40 - 16:50Discussion Controversy
16:50 - 17:10O8.2 Predictive biomarker evaluations and immunophenotyping in immunotherapy: the INSPIRE clinical trial [More Info]
Derek Clouthier, Princess Margaret Cancer Centre / University Health Network, Toronto, Canada
17:10 - 17:30O8.3 Decision support for genomically-selected trials [More Info]
Filip Janku, The University Texas MD Anderson Cancer Center, Houston, TX, USA
17:30 - 17:50General discussion
 
Wednesday, March 8, 2017


08:30 - 10:10Plenary Session 9: Targeting cancer metabolism [More Info]
Chair: Susan Bates, Columbia University, New York, NY, USA
Chair: Antoine Italiano, Institut Bergonié, Bordeaux, France
08:30 - 08:50O9.1 Cancer cell metabolism and its vulnerabilities [More Info]
Guido Kroemer, University Paris Descartes, Paris, France
08:50 - 09:10O9.2 Metabolic targets in renal cell cancer [More Info]
Brian Shuch, Yale University, New Haven, CT, USA
09:10 - 09:30O9.3 Targeting Mitochondrial Protein Complex 1 [More Info]
Anthony Tolcher, South Texas Accelerated Research Therapeutics, San Antonio, TX, USA
09:30 - 09:50O9.4 Liver-X-Receptor Inverse Agonists as Anti-Cancer Therapies that Targets the Warburg Effect and Lipogenesis [More Info]
Colin Flaveny, Saint Louis University, Saint Louis, MO, USA
09:50 - 10:10General discussion


10:10 - 10:35Break


10:35 - 12:20Plenary Session 10: Miscellaneous drugs, targets and methods [More Info]
Chair: Ruth Plummer, Newcastle University, Newcastle upon Tyne, United Kingdom
Chair: Geoffrey Shapiro, Dana-Farber Cancer Institute, Boston, MA, USA
10:35 - 10:55O10.1 Targeting the Epigenome [More Info]
Susan Bates, Columbia University, New York, NY, USA
10:55 - 11:15O10.2 Epigenetic priming for immunotherapy: what progress has there been in the promise? [More Info]
Nilofer Azad, Johns Hopkins University, Baltimore, MD, USA
11:15 - 11:35O10.3 CDK8/19: a new transcriptional target for cancer therapy [More Info]
Igor Roninson, University of South Carolina, Columbia, SC, USA
11:35 - 11:45O10.4 Lurbinectedin inhibits active transcription affecting tumor cell burden and its inflammatory microenvironment [More Info]
Carlos Galmarini, PharmaMar, Madrid, Spain
Jean-Marc Egly, IGBMC, CNRS, INSERM, University of Strasbourg, Strasbourg, France
11:45 - 11:55O10.5 Entering the era of clinical proteomics: Utilizing multiplexed targeted proteomics to guide patient care [More Info]
Todd Hembrough, Nantomics, Rockville, MD, USA
11:55 - 12:05O10.6 Initial perspectives from WINTHER, an international precision medicine trial using both DNA and RNA data to guide treatment [More Info]
Vladimir Lazar, Worldwide Innovative Networking (WIN) Consortium, Villejuif, France
12:05 - 12:20General discussion


12:20 - 13:00Lunch


13:00 - 14:15Plenary Session 11: DNA-targeted therapies [More Info]
Chair: Yves Pommier, National Cancer Institute, Bethesda, MD, USA
Chair: Patricia LoRusso, Yale Cancer Center, New Haven, CT, USA
13:00 - 13:20O11.1 Tumor DNA Targeting: It is time to wake up [More Info]
Yves Pommier, National Cancer Institute, Bethesda, MD, USA
13:20 - 13:40O11.2 DNA- and Tumor-Targeted Targeted Precision Medicine [More Info]
Anish Thomas, National Cancer Institute, Bethesda, MD, USA
13:40 - 14:00O11.3 Novel synthetic lethal approaches: beyond BRCA and DNA repair [More Info]
Christopher Lord, Institute of Cancer Research, London, UK
14:00 - 14:15General discussion


14:20 - 15:35Plenary Session 12: New targets in the androgen receptor pathway [More Info]
Chair: Christophe Massard, Institut Gustave Roussy, Villejuif, France
Chair: Sophie Postel-Vinay, Institut Gustave Roussy, Villejuif, France
14:20 - 14:40O12.1 Precision medicine in prostate cancer: Androgen Receptors pathway, biology and therapeutics [More Info]
Bertrand Tombal, Cliniques universitaires Saint Luc, Brussels, Belgium
14:40 - 15:00O12.2 DNA repair and prostate cancer: from genetics to targeted therapies [More Info]
David Olmos, Spanish National Cancer Research Centre & Institute of Biomedical Research in Malaga, Madrid, Spain
15:00 - 15:20O12.3 Immunotherapy of Prostate Cancer [More Info]
Lawrence Fong, University of California, San Francisco, CA, USA
15:20 - 15:35General discussion


15:35 - 15:40Closing remarks [More Info]
Jean-Charles Soria, Institut Gustave Roussy, Villejuif, France